TGF-β1 polymorphisms and asthma severity, airway inflammation, and remodeling - 30/01/13
Doi : 10.1016/j.jaci.2012.08.013
Despo Ierodiakonou, MD a, e, Dirkje S. Postma, MD, PhD b, e, Gerard H. Koppelman, MD, PhD c, e, Jorrit Gerritsen, MD, PhD c, e, Nick H.T. ten Hacken, MD, PhD b, e, Wim Timens, MD, PhD d, e, H. Marike Boezen, PhD a, e, Judith M. Vonk, PhD a, e 
a Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
b Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
c Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
d Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
e Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| Disclosure of potential conflict of interest: D. S. Postma has received research support from Nycomed and GlaxoSmithKline; has consultant arrangements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Nycomed, and TEVA; and was supported by an unrestricted educational grant for research from AstraZeneca, Chiesi, and GlaxoSmithKline; travel to ERS and/or ATS has been partially funded by AstraZeneca, Chiesi, GlaxoSmithKline, and Nycomed; fees for consultancies were given to the University of Groningen by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Nycomed, and TEVA. G. H. Koppelman received grant support from the Netherlands Asthma Foundation and NWO-Biobanking and Biomolecular Resources Research Infrastructure. N. H. T. Hacken received grant support from Chiesi, GlaxoSmithKline, Nycomed, AstraZEneca, and Danone. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2012
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 131 - N° 2
P. 582-585 - février 2013 Retour au numéro
Article précédent
- Prophylactic therapy in children with hereditary angioedema
- Henriette Farkas, Dorottya Csuka, Zsuzsanna Zotter, Lilian Varga, George Füst
- Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center
- Thierry Ducruet, Marie-Claude Levasseur, Anne Des Roches, Ayman Kafal, Renée Dicaire, Elie Haddad
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?